



DIFICID

Products Affected

Step 2:

- DIFICID SUSPENSION
RECONSTITUTED 40 MG/ML ORAL
- DIFICID TABLET 200 MG ORAL

Details

Criteria	Claim will pay automatically for Difucid if enrollee has a paid claim for at least a 1 day supply of vancomycin or Firvanq in the past 120 days. Otherwise, Difucid requires a step therapy exception request indicating: (1) history of inadequate treatment response with vancomycin or Firvanq, OR (2) history of adverse event with vancomycin or Firvanq, OR (3) vancomycin or Firvanq is contraindicated.
-----------------	---



RYTARY

Products Affected

Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated.
-----------------	--



Index

D

DIFICID SUSPENSION
RECONSTITUTED 40 MG/ML ORAL 1
DIFICID TABLET 200 MG ORAL 1

R

RYTARY CAPSULE EXTENDED
RELEASE 23.75-95 MG ORAL 2

RYTARY CAPSULE EXTENDED
RELEASE 36.25-145 MG ORAL 2
RYTARY CAPSULE EXTENDED
RELEASE 48.75-195 MG ORAL 2
RYTARY CAPSULE EXTENDED
RELEASE 61.25-245 MG ORAL 2